Telesis Bio, Inc.

Symbol: TBIO

NASDAQ

0.331

USD

Market price today

  • -0.2081

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 9.96M

    MRK Cap

  • 0.00%

    DIV Yield

Telesis Bio, Inc. (TBIO) Financial Statements

On the chart you can see the default numbers in dynamics for Telesis Bio, Inc. (TBIO). Companys revenue shows the average of 9.848 M which is 0.615 % gowth. The average gross profit for the whole period is 4.213 M which is 0.081 %. The average gross profit ratio is 0.266 %. The net income growth for the company last year performance is -0.015 % which equals -0.450 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Telesis Bio, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.135. In the realm of current assets, TBIO clocks in at 30.351 in the reporting currency. A significant portion of these assets, precisely 19.333, is held in cash and short-term investments. This segment shows a change of -0.558% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 5.269 in the reporting currency. This figure signifies a year_over_year change of 0.605%. Shareholder value, as depicted by the total shareholder equity, is valued at 29.538 in the reporting currency. The year over year change in this aspect is -1.260%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 5.985, with an inventory valuation of 4.03, and goodwill valued at 3.5, if any. The total intangible assets, if present, are valued at 1.37. Account payables and short-term debt are 3.28 and 1.82, respectively. The total debt is 34.38, with a net debt of 32.63. Other current liabilities amount to 2.74, adding to the total liabilities of 40.87. Lastly, the referred stock is valued at 29.3, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

140.5619.343.882.8
13.5
29.1
144.1
58.1
70.7

balance-sheet.row.short-term-investments

51.117.613.20
0
0
88.9
10
13

balance-sheet.row.net-receivables

25.4265.93.7
2.3
1.5
0
0
0

balance-sheet.row.inventory

14.4542.22.4
0.6
0.7
0
0
0

balance-sheet.row.other-current-assets

6.9413.34.3
0.9
0.1
5.5
5
1.7

balance-sheet.row.total-current-assets

187.5530.455.193.2
17.2
31.4
149.6
63
72.4

balance-sheet.row.property-plant-equipment-net

133.734.58.55.7
3.8
0.9
10.2
6.8
4.9

balance-sheet.row.goodwill

48.163.514.914.3
3.5
3.5
21.4
21.4
21.4

balance-sheet.row.intangible-assets

6.241.41.92.4
2.3
2.9
106.4
106.8
106.8

balance-sheet.row.goodwill-and-intangible-assets

54.44.916.816.7
5.8
6.4
127.8
128.2
128.2

balance-sheet.row.long-term-investments

0000
0
0
0
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0
0

balance-sheet.row.other-non-current-assets

3.480.710.6
0.1
0.1
0
0.5
0.1

balance-sheet.row.total-non-current-assets

191.5840.126.323.1
9.7
7.3
138
135.5
133.1

balance-sheet.row.other-assets

0000
0
0
0
0
0

balance-sheet.row.total-assets

379.1370.481.4116.3
26.9
38.8
287.7
198.5
205.6

balance-sheet.row.account-payables

9.553.31.32.5
1.2
0.6
5.2
4.6
0.5

balance-sheet.row.short-term-debt

21.11.80.61.8
2.1
0.1
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0

balance-sheet.row.long-term-debt-total

126.895.320.815.5
6.2
4.7
-34.6
0
0

Deferred Revenue Non Current

0.50.10.10.1
0
0
41.8
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

27.29---
-
-
-
-
-

balance-sheet.row.other-current-liab

17.912.77.65.2
1.7
0.9
6.5
7.5
11.5

balance-sheet.row.total-non-current-liabilities

155.1832.721.315.7
46.7
44.5
148.1
280
232.1

balance-sheet.row.other-liabilities

28.15000
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

108.1827.31.82.6
3.6
0.3
0
0
0

balance-sheet.row.total-liab

238.5740.934.825.5
52.3
46.3
162.4
292.1
244.2

balance-sheet.row.preferred-stock

86.1729.300
38.9
38.9
0
0
0

balance-sheet.row.common-stock

0.02000
0
0
0
0
0

balance-sheet.row.retained-earnings

-563.25-161.5-113.7-65.3
-26.3
-8.3
-246.2
-148.8
-82.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.02000
-38.9
-38.9
0.2
0.1
0

balance-sheet.row.other-total-stockholders-equity

295.09161.70156
0.9
0.8
371.3
55.2
43.8

balance-sheet.row.total-stockholders-equity

-181.9829.5-113.790.8
-25.5
-7.5
125.3
-93.5
-38.6

balance-sheet.row.total-liabilities-and-stockholders-equity

217.6570.4-78.9116.3
26.9
38.8
287.7
198.5
205.6

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

-181.9829.5-113.790.8
-25.5
-7.5
125.3
-
-

balance-sheet.row.total-liabilities-and-total-equity

217.65---
-
-
-
-
-

Total Investments

51.117.613.20
0
0
88.9
10
13

balance-sheet.row.total-debt

175.2834.421.417.3
8.3
4.8
0
0
0

balance-sheet.row.net-debt

86.1732.6-9-65.5
-5.1
-24.4
-55.2
-48.1
-57.7

Cash Flow Statement

The financial landscape of Telesis Bio, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.151. The company recently extended its share capital by issuing 26.66, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -5744000.000 in the reporting currency. This is a shift of -0.681 from the previous year. In the same period, the company recorded 4.1, 0, and -15.09, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

cash-flows.row.net-income

-47.72-47.7-48.5-39
-18
-8.3
-97.4
-66.4
-26.7

cash-flows.row.depreciation-and-amortization

4.14.12.91.6
1.5
0.9
2.8
1.6
0.7

cash-flows.row.deferred-income-tax

-6.39-18.602.3
0.4
-0.5
-5.6
-12.5
0

cash-flows.row.stock-based-compensation

3.9643.71.1
0
0
7.3
3.7
0.7

cash-flows.row.change-in-working-capital

-7.77-7.82.1-3
0
0.2
84.4
-9.5
1.1

cash-flows.row.account-receivables

-1.33-1.3-2.2-0.7
-0.8
-0.9
0
0
0

cash-flows.row.inventory

-1.82-1.80.2-1.5
0.1
0.7
0
0
0

cash-flows.row.account-payables

-1.81-3.31.2-0.3
0.1
0.2
0.7
4
0.1

cash-flows.row.other-working-capital

-2.8-1.33-0.5
0.5
0.1
83.7
-13.5
1

cash-flows.row.other-non-cash-items

19.1431.410.3
0.7
1.3
-13.7
32.4
0.5

cash-flows.row.net-cash-provided-by-operating-activities

-34.67000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-1.98-2-4.5-1.9
-0.2
-0.1
-6.6
-2.8
-0.9

cash-flows.row.acquisitions-net

-4.580-0.6-13.2
0
0
0
0
0

cash-flows.row.purchases-of-investments

-33.77-33.8-77.40
0
-174.3
-136.7
-70.8
-34.9

cash-flows.row.sales-maturities-of-investments

303064.40
0
159.6
58
73.8
41.9

cash-flows.row.other-investing-activites

4.59000
0
14.6
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

-5.74-5.7-18-15
-0.2
-0.1
-85.3
0.3
6.1

cash-flows.row.debt-repayment

-15.09-15.1-15.1-5.1
-0.1
-2.3
0
0
0

cash-flows.row.common-stock-issued

26.6626.70.5112.5
0
33
117.4
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

-0.02019.113.7
-0.1
-0.1
-3.8
41.7
50.7

cash-flows.row.net-cash-used-provided-by-financing-activities

11.5611.64.5121.1
-0.1
35.1
113.6
41.7
50.7

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0.7
0
0
0

cash-flows.row.net-change-in-cash

-28.85-28.8-52.269.3
-15.7
-27.1
6.2
-8.7
33.1

cash-flows.row.cash-at-end-of-period

89.631.730.682.8
13.5
29.1
56.2
50
58.8

cash-flows.row.cash-at-beginning-of-period

118.4830.682.813.5
29.1
56.2
50
58.8
25.6

cash-flows.row.operating-cash-flow

-34.67-34.7-38.7-36.7
-15.4
-6.4
-22.1
-50.8
-23.7

cash-flows.row.capital-expenditure

-1.98-2-4.5-1.9
-0.2
-0.1
-6.6
-2.8
-0.9

cash-flows.row.free-cash-flow

-36.65-36.6-43.2-38.6
-15.6
-6.5
-28.7
-53.6
-24.6

Income Statement Row

Telesis Bio, Inc.'s revenue saw a change of 0.003% compared with the previous period. The gross profit of TBIO is reported to be 12.85. The company's operating expenses are 48, showing a change of -22.684% from the last year. The expenses for depreciation and amortization are 4.1, which is a -158.769% change from the last accounting period. Operating expenses are reported to be 48, which shows a -22.684% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.244% year-over-year growth. The operating income is -35.15, which shows a -0.244% change when compared to the previous year. The change in the net income is -0.015%. The net income for the last year was -47.72.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

income-statement-row.row.total-revenue

27.5127.527.411
6.6
4.8
1.4
0
0

income-statement-row.row.cost-of-revenue

11.2114.711.86.7
3
8.9
0
0
0

income-statement-row.row.gross-profit

16.312.815.64.3
3.6
-4.1
1.4
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

16.84---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

21.09---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

13.51---
-
-
-
-
-

income-statement-row.row.other-expenses

-0.13-0.10-0.1
-0.1
0
0
0
0

income-statement-row.row.operating-expenses

51.454862.139.7
20
2.9
80.6
61.3
26.8

income-statement-row.row.cost-and-expenses

62.6662.773.946.4
22.9
11.8
80.6
61.3
26.8

income-statement-row.row.interest-income

11.71.21.4
0.7
1.8
1.3
0.3
0.1

income-statement-row.row.interest-expense

3.13.11.21.4
0.7
1.5
0
0
0

income-statement-row.row.selling-and-marketing-expenses

13.51---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-11.53-12.6-2-3.6
-1.6
-1.3
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

-0.13-0.10-0.1
-0.1
0
0
0
0

income-statement-row.row.total-operating-expenses

-11.53-12.6-2-3.6
-1.6
-1.3
0
0
0

income-statement-row.row.interest-expense

3.13.11.21.4
0.7
1.5
0
0
0

income-statement-row.row.depreciation-and-amortization

2.934.101.5
1.4
0.9
2.8
1.6
0.7

income-statement-row.row.ebitda-caps

-33.16---
-
-
-
-
-

income-statement-row.row.operating-income

-35.15-35.1-46.5-35.4
-16.4
-7
-103
-78.9
-26.7

income-statement-row.row.income-before-tax

-47.7-47.7-48.4-38.9
-18
-8.3
-103
-78.9
-26.7

income-statement-row.row.income-tax-expense

0.02000
0
-0.5
-5.6
-12.5
0

income-statement-row.row.net-income

-47.72-47.7-48.5-39
-18
-8.3
-97.4
-66.4
-26.7

Frequently Asked Question

What is Telesis Bio, Inc. (TBIO) total assets?

Telesis Bio, Inc. (TBIO) total assets is 70411000.000.

What is enterprise annual revenue?

The annual revenue is 12541000.000.

What is firm profit margin?

Firm profit margin is 0.592.

What is company free cash flow?

The free cash flow is -1.221.

What is enterprise net profit margin?

The net profit margin is -1.735.

What is firm total revenue?

The total revenue is -1.278.

What is Telesis Bio, Inc. (TBIO) net profit (net income)?

The net profit (net income) is -47724000.000.

What is firm total debt?

The total debt is 34380000.000.

What is operating expences number?

The operating expences are 47998000.000.

What is company cash figure?

Enretprise cash is 1745000.000.